Observational Study of Early Rebiopsy in NSCLC with Targeted Therapies
This observational study aims to understand how lung cancer cells change early in response to targeted treatments like Tyrosine Kinase Inhibitors (TKIs). Researchers will compare tumor characteristics at the beginning of treatment to those after about two weeks. This helps identify how cancer cells survive and adapt, which could lead to better ways to combine treatments and improve outcomes. You may be eligible if you have locally advanced or stage IV non-small cell lung cancer (NSCLC) with specific gene mutations (EGFR, ALK, ROS1, or BRAF) that respond to targeted therapies, are aged 18 to 85, and have an ECOG score of 0-2 (meaning you are fully active or can care for yourself with some limitations). The study is currently unclear on its recruitment status.
- Study design
- This is an observational study with a planned enrollment of 100 participants. It is not specified if it is randomized or blinded.
- What's involved
- Participants will have tumor characteristics measured at the start of the study and again approximately two weeks later. This involves a biopsy and blood draw.
- Compensation
- Not stated in the trial record.
- Follow-up
- Gene and protein expression changes are measured at baseline and at 2 weeks (+/- 1 week) for each patient.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Erin Schenk · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- gene expression changesbaseline and 2 weeks (+/- 1 week) for each patient.
change from baseline of tumor gene expression profile at 2 weeks. Global gene expression data will be collected using RNAseq
- protein expression changebaseline and 2 weeks (+/- 1 week) for each patient.
change from baseline of protein gene expression profile at 2 weeks as measured by multiplex protein assay (proteins to be assayed include: e-cadherin, vimentin, fibronectin, CD4, CD8, CD14, CD16, CD206, PDL1, and CSF1R)